Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of pregabalin administered twice a day compared to
placebo in reducing pain in subjects with painful diabetic peripheral neuropathy.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.